[go: up one dir, main page]

EA201291416A1 - Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1 - Google Patents

Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1

Info

Publication number
EA201291416A1
EA201291416A1 EA201291416A EA201291416A EA201291416A1 EA 201291416 A1 EA201291416 A1 EA 201291416A1 EA 201291416 A EA201291416 A EA 201291416A EA 201291416 A EA201291416 A EA 201291416A EA 201291416 A1 EA201291416 A1 EA 201291416A1
Authority
EA
Eurasian Patent Office
Prior art keywords
polypeptides
insulin
receptor
growth factor
disclosed
Prior art date
Application number
EA201291416A
Other languages
English (en)
Other versions
EA023541B1 (ru
Inventor
Майкл Дим
Карин О'Нил
Original Assignee
Янссен Байотек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Байотек, Инк. filed Critical Янссен Байотек, Инк.
Publication of EA201291416A1 publication Critical patent/EA201291416A1/ru
Publication of EA023541B1 publication Critical patent/EA023541B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

Раскрываются полипептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1, и полинуклеотиды, кодирующие такие полипептиды. Также раскрываются способы получения полипептидов с использованием клеточных систем экспрессии и бесклеточных систем, а также способы использования полипептидов для получения слитых белков. Раскрытые полипептиды могут обеспечивать возможность доставки терапевтических агентов через гематоэнцефалический барьер.
EA201291416A 2010-05-27 2011-05-25 Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1 EA023541B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34893710P 2010-05-27 2010-05-27
PCT/US2011/037904 WO2011150061A1 (en) 2010-05-27 2011-05-25 Insulin-like growth factor 1 receptor binding peptides

Publications (2)

Publication Number Publication Date
EA201291416A1 true EA201291416A1 (ru) 2013-06-28
EA023541B1 EA023541B1 (ru) 2016-06-30

Family

ID=45004356

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201291416A EA023541B1 (ru) 2010-05-27 2011-05-25 Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1

Country Status (27)

Country Link
US (1) US8415306B2 (ru)
EP (1) EP2575846B1 (ru)
JP (1) JP5864556B2 (ru)
KR (1) KR101898502B1 (ru)
CN (1) CN103025341B (ru)
AU (1) AU2011258301B2 (ru)
BR (1) BR112012030084B1 (ru)
CA (1) CA2800744C (ru)
CY (1) CY1116757T1 (ru)
DK (1) DK2575846T3 (ru)
EA (1) EA023541B1 (ru)
ES (1) ES2550040T3 (ru)
HR (1) HRP20151084T1 (ru)
HU (1) HUE026269T2 (ru)
IL (1) IL223030A (ru)
ME (1) ME02206B (ru)
MX (1) MX337134B (ru)
NZ (1) NZ603611A (ru)
PL (1) PL2575846T3 (ru)
PT (1) PT2575846E (ru)
RS (1) RS54278B1 (ru)
SG (1) SG186068A1 (ru)
SI (1) SI2575846T1 (ru)
SM (1) SMT201500222B (ru)
UA (1) UA107596C2 (ru)
WO (1) WO2011150061A1 (ru)
ZA (1) ZA201209689B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014385801B2 (en) * 2014-03-06 2020-11-12 National Research Council Of Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
KR102355308B1 (ko) * 2014-03-06 2022-01-24 내셔날 리서치 카운실 오브 캐나다 인슐린-유사 성장 인자 1 수용체-특이적 항체 및 그의 용도
JP6541237B2 (ja) * 2014-03-06 2019-07-10 ナショナル リサーチ カウンシル オブ カナダ インスリン様成長因子１受容体特異的抗体及びそれらの使用
JP6463499B2 (ja) 2015-12-21 2019-02-06 ブラインオン， インク 記憶力、学習力、認知力向上用組成物
KR101706296B1 (ko) 2015-12-21 2017-02-13 주식회사 브레인온 기억력, 학습력, 인지력 향상용 조성물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
JPH06228199A (ja) * 1992-11-27 1994-08-16 Takeda Chem Ind Ltd 血液脳関門通過可能なペプチド結合体
EP1006184A1 (en) * 1998-12-03 2000-06-07 F. Hoffmann-La Roche Ag IGF-1 receptor interacting proteins (IIPs) genes coding therefor and uses thereof
US20090087878A9 (en) 1999-05-06 2009-04-02 La Rosa Thomas J Nucleic acid molecules associated with plants
US20100293669A2 (en) 1999-05-06 2010-11-18 Jingdong Liu Nucleic Acid Molecules and Other Molecules Associated with Plants and Uses Thereof for Plant Improvement
AU6607100A (en) * 1999-07-23 2001-02-13 Regents Of The University Of California, The Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
KR100619612B1 (ko) 1999-10-04 2006-09-01 넥타르 테라퓨틱스 에이엘, 코포레이션 폴리머 안정화 신경펩타이드
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
KR20030036835A (ko) 2000-09-26 2003-05-09 제넨테크, 인크. Ｉｇｅ 수용체 길항제
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
EP1494712A4 (en) * 2002-03-26 2006-06-14 Centocor Inc MULTIPLE SCLEROSIS RELATED PROTEINS, COMPOSITIONS, PROCESSES AND APPLICATIONS DERIVED FROM IMMUNOGLOBULIN
US7388079B2 (en) * 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US8017151B2 (en) 2004-09-07 2011-09-13 Board Of Regents Of The University Of Nebraska By And Behalf Of The University Of Nebraska Medical Center Amphiphilic polymer-protein conjugates and methods of use thereof
EP1896505A2 (en) * 2005-06-15 2008-03-12 Schering Corporation Anti-igf1r antibody formulations
US8142781B2 (en) 2005-10-07 2012-03-27 Armagen Technologies, Inc. Fusion proteins for blood-brain barrier delivery
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them
CN101842116A (zh) 2007-08-28 2010-09-22 比奥根艾迪克Ma公司 结合igf-1r多个表位的组合物
WO2009085462A1 (en) 2007-12-19 2009-07-09 Centocor, Inc. Design and generation of human de novo pix phage display libraries via fusion to pix or pvii, vectors, antibodies and methods

Also Published As

Publication number Publication date
WO2011150061A1 (en) 2011-12-01
SI2575846T1 (sl) 2015-09-30
CY1116757T1 (el) 2017-03-15
CA2800744C (en) 2018-09-04
KR101898502B1 (ko) 2018-09-13
CN103025341A (zh) 2013-04-03
PL2575846T3 (pl) 2015-12-31
US20110294748A1 (en) 2011-12-01
JP2013534811A (ja) 2013-09-09
SG186068A1 (en) 2013-01-30
EA023541B1 (ru) 2016-06-30
CN103025341B (zh) 2015-07-22
ZA201209689B (en) 2014-05-28
RS54278B1 (en) 2016-02-29
SMT201500222B (it) 2015-10-30
IL223030A (en) 2016-11-30
EP2575846B1 (en) 2015-07-15
UA107596C2 (uk) 2015-01-26
PT2575846E (pt) 2015-09-16
CA2800744A1 (en) 2011-12-01
KR20130111237A (ko) 2013-10-10
JP5864556B2 (ja) 2016-02-17
HUE026269T2 (en) 2016-06-28
ME02206B (me) 2016-02-20
AU2011258301B2 (en) 2013-11-21
BR112012030084B1 (pt) 2020-04-14
US8415306B2 (en) 2013-04-09
EP2575846A4 (en) 2013-12-11
EP2575846A1 (en) 2013-04-10
MX2012013710A (es) 2013-05-20
IL223030A0 (en) 2013-02-03
BR112012030084A2 (pt) 2017-06-20
HRP20151084T1 (hr) 2015-11-06
DK2575846T3 (en) 2015-08-10
MX337134B (es) 2016-02-12
AU2011258301A1 (en) 2012-12-06
ES2550040T3 (es) 2015-11-04
NZ603611A (en) 2014-12-24
HK1183234A1 (zh) 2013-12-20

Similar Documents

Publication Publication Date Title
CY1120637T1 (el) Πολυπεπτιδικα αντισωματα που ανταγωνιζονται cd40
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
UA115120C2 (uk) Спосіб застосування химерного поліпептиду фактора ix
EA201590525A1 (ru) Слитые белки для лечения метаболического синдрома
NZ800822A (en) Fibronectin based scaffold domain proteins that bind to myostatin
CA2889275C (en) Novel method for treating cardiac infarction using hmgb1 fragment
AR075029A1 (es) Metodo para producir una proteina o un peptido fisiologicamente activo usando un fragmento de inmunoglobulina
EA201691109A1 (ru) Химерные и гибридные полипептиды фактора viii-fc и способы их применения
CY1121466T1 (el) Αντισωματα εναντι προσδεματων υποδοχεα β1 βραδυκινινης
EA201201435A1 (ru) ГЕТЕРОДИМЕРНЫЕ АНТИТЕЛО-Fc-СОДЕРЖАЩИЕ БЕЛКИ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EA201690377A1 (ru) Антитела к ингибитору активатора плазминогена 1 (pai-1) и пути их применения
EA201590705A1 (ru) ПОЛУЧЕНИЕ РЕКОМБИНАНТНОЙ ВАКЦИНЫ В E.coli ПОСРЕДСТВОМ ЭНЗИМАТИЧЕСКОЙ КОНЪЮГАЦИИ
CR20110221A (es) Terapia de combinación con péptidos epoxicetonas peptídicas
EA201000018A1 (ru) Лиофилизированные лекарственные формы иммуноглобулинов и способы их получения
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA201890389A3 (ru) Композиции конъюгата xten и способы их получения
EA201290069A1 (ru) Модифицированные полипептиды фактора ix и их применения
MX360741B (es) Constructos de polipéptidos y sus usos.
MA34077B1 (fr) Nouveau peptides et procedes pour leur preparation, ain que leur utilisation
PE20140982A1 (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
CL2007001710A1 (es) Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras.
WO2012068317A3 (en) Methods for producing recombinant proteins
EA201600141A1 (ru) Терапевтический слитый белок
NZ713602A (en) Method for refining protein including self-cutting cassette and use thereof
EA201291416A1 (ru) Пептиды, связывающиеся с рецептором инсулиноподобного фактора роста 1